The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies

[1] Vétizou M(2015)Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota Science 350 1079-1084

[2] Pitt JM(2015)Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy Science 350 1084-1089

[3] Daillère R(2018)Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients Science 359 97-103

[4] Lepage P(2017)Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab Ann Oncol 28 1368-1379

[5] Waldschmitt N(2019)Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics Ann Oncol 30 652-653

[6] Flament C(2018)Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors OncoImmunology 7 e1507670-1444

[7] Rusakiewicz S(2018)Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer Ann Oncol 29 1437-6

[8] Routy B(2019)Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors OncoImmunology 8 1-3200

[9] Roberti MP(2017)Antibiotic use does not appear to influence response to Nivolumab Anticancer Res 37 3195-97

[10] Duong CP(2007)Practical methods for incorporating summary time-to-event data into meta-analysis Trials 8 16-16520

[1] Vétizou M(2015)Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota Science 350 1079-1084

[2] Pitt JM(2015)Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy Science 350 1084-1089

[3] Daillère R(2018)Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients Science 359 97-103

[4] Lepage P(2017)Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab Ann Oncol 28 1368-1379

[5] Waldschmitt N(2019)Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics Ann Oncol 30 652-653

[6] Flament C(2018)Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors OncoImmunology 7 e1507670-1444

[7] Rusakiewicz S(2018)Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer Ann Oncol 29 1437-6

[8] Routy B(2019)Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors OncoImmunology 8 1-3200

[9] Roberti MP(2017)Antibiotic use does not appear to influence response to Nivolumab Anticancer Res 37 3195-97

[10] Duong CP(2007)Practical methods for incorporating summary time-to-event data into meta-analysis Trials 8 16-16520